Sandy Srinivas, MD, on Treatment Alternatives for Metastatic Castration-Resistant Prostate Cancer During Radioligand Therapy Shortage

Posted: Wednesday, May 10, 2023

Sandy Srinivas, MD, of Stanford University School of Medicine, discusses alternative treatment options for patients who have metastatic castration-resistant prostate cancer and are awaiting the availability of the radioligand therapy lutetium Lu 177 vipivotide tetraxetan.

---